Scotia Foscan Shows Increased Response Rate In August Trial Update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Updated results for the pivotal Phase II/III trial of Scotia’s photodynamic therapy Foscan (temoporfin) demonstrated a 17% complete tumor response rate and an 11% partial response rate in 64 patients with advanced, inoperable head and neck cancer. The firm reported the follow-up data at the 5th International Conference on Head and Neck Cancer August 1 in San Francisco.